Targeted Lipid Nanoparticle Composition for HSC and Immune Cell Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for safe and effective in vivo methods for targeted expression of immune cell function enhancing polypeptides in immune cells and targeted gene editing in hematopoietic stem cells.
Innovation Solution
Lipid nanoparticles comprising an ionizable lipid, a structural lipid, a helper lipid, a PEG lipid, and a cell-targeting group are developed for targeted delivery of nucleic acids to hematopoietic stem cells and immune cells, with specific compositions and ratios of these lipids to enhance delivery efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional lipid nanoparticle formulations are used for nucleic acid delivery, then delivery to some cells is achieved, but delivery efficiency to hematopoietic stem cells and immune cells is insufficient
Solution Approach 1:
The patent applies local quality by incorporating a cell-targeting group (such as an antibody or ligand) onto the lipid nanoparticle surface that specifically recognizes and binds to receptors on hematopoietic stem cells or immune cells. This localized targeting capability ensures that the nucleic acid delivery is concentrated at the desired cell type rather than distributed broadly, thereby improving both delivery efficiency and targeted delivery reliability simultaneously.
2Quantity of substance
If high concentrations of nucleic acids are delivered to achieve therapeutic effect, then treatment efficacy improves, but off-target effects and toxicity increase
Solution Approach 1:
The patent uses a cell-targeting group as an intermediary that mediates between the lipid nanoparticle and the target cell. This intermediary ensures high-affinity specific binding to the desired cell type (hematopoietic stem cells or immune cells), allowing high concentrations of nucleic acids to be delivered precisely to the target while minimizing off-target delivery and associated toxicity.
3Productivity
If lipid nanoparticle composition is optimized for high delivery efficiency, then transfection efficiency improves, but formulation complexity increases
Solution Approach 1:
The patent employs composite materials by combining ionizable lipids with cell-targeting groups (such as antibodies or ligands) on the nanoparticle surface. This composite structure integrates both the transfection function of the ionizable lipid and the targeting function of the cell-targeting group, achieving high transfection efficiency while maintaining a unified formulation rather than requiring separate targeting and delivery systems.
Data Source
AI summary
Provided are lipid nanoparticles, compositions, and methods of making and using the same. The lipid nanoparticles contain ionizable lipids, structural lipids, PEG lipids and specific amounts of helper lipids. The lipid nanoparticles may further contain a cell targeting group coupled to a PEG lipid. The lipid nanoparticles may carry a cargo, e g., a mRNA. The lipid nanoparticles may be used for transfection of cells, e.g., immune cells or hematopoietic stem cells.